Eisai to Present Latest Data at 10th Clinical Trials on Alzheimer's Diesase
2017年10月31日 - 11:27AM
JCN Newswire (英)
Eisai Co., Ltd. announced today that the latest data on its oral
dual orexin receptor antagonist lemborexant and its oral beta
secretase cleaving enzyme (BACE) inhibitor elenbecestat(1) will be
presented at the 10th Clinical Trials on Alzheimer's Disease
(CTAD), taking place in Boston, the United States, from November 1
to 4.
At the CTAD meeting, there will be a poster presentation on the
characteristics of sleep and wakefulness measured by actigraphy(2)
in patients with Irregular Sleep-Wake Rhythm Disorder (ISWRD) and
Alzheimer's disease (AD) dementia. This is the first clinical study
of lemborexant to assess the circadian rhythm of sleep-wake
patterns in this patient population. ISWRD is a type of circadian
rhythm sleep disorder where the pattern of sleep and wakefulness
that repeats itself over a 24-hour period in healthy individuals is
broken down, and sleeping and waking occur instead at various times
during the day and night. It is a common comorbid condition in AD,
appears early in the course of disease, and is associated with many
of the behavioral disturbances in AD patients such as agitation,
restlessness and wandering. For elenbecestat, there are two poster
presentations scheduled, including a presentation on the use of the
International Shopping List Test as the objective assessment of
cognitive impairment to identify subjects with early Alzheimer's
disease in the phase 3 clinical trials.
Lemborexant, a dual orexin receptor antagonist, is an in-house
discovered novel small molecule which inhibits orexin by binding
competitively to two subtypes of orexin receptors (orexin receptor
1 and 2). Lemborexant is being jointly developed by Eisai and
Purdue Pharma L.P. Elenbecestat, its in-house discovered BACE
inhibitor, is being jointly developed by Eisai and Biogen Inc. Two
global Phase 3 clinical studies (known as MISSIONAD1 and
MISSIONAD2) are ongoing in patients with early AD. In addition, the
U.S. Food and Drug Administration (FDA) has granted Fast Track
designation for the development of elenbecestat, a process allowing
priority reviews by the FDA for drugs deemed as having potential to
treat serious conditions and tackle key unmet medical needs.
Furthermore, there will be several oral presentations for anti-A
beta antibody aducanumab. Eisai has exercised its option to jointly
develop and commercialize aducanumab with Biogen.
Eisai considers dementia a therapeutic area of focus and is
committed to new drug development in this field. Eisai strives to
bring promising therapies to patients worldwide as early as
possible.
(1) The generic name is not yet fixed at this time.
(2) Actigraphy is a non-invasive method for measuring and assessing
the circadian rhythm of sleep-wake patterns continuously over
several weeks through a device worn on the wrist.
About Eisai
Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human
health care (hhc) company that discovers, develops and markets
products throughout the world. Eisai focuses its efforts in three
therapeutic areas: integrative neuroscience, including neurology
and psychiatric medicines; integrative oncology, which encompasses
oncotherapy and supportive-care treatments; and
vascular/immunological reaction. Through a global network of
research facilities, manufacturing sites and marketing
subsidiaries, Eisai actively participates in all aspects of the
worldwide healthcare system. For more information about Eisai Co.,
Ltd., please visit www.eisai.com.
Source: Eisai
Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Copyright 2017 JCN Newswire . All rights reserved.